Claims
- 1. A method of treating or inhibiting inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula I, having the structure
- 2. The method according to claim 1, wherein the compound provided is 6-hydroxy-3,17β-dihydroequilenin, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate thereof, or a glucuronide thereof.
- 3. The method according to claim 1, wherein the compound provided is 6-hydroxyequilenin, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate thereof, or a glucuronide thereof.
- 4. A method of treating or inhibiting prostatic hypertrophy, uterine leiomyomas, breast cancer, endometriosis, endometrial cancer, polycystic ovary syndrome, endometrial polyps, benign breast disease, adenomyosis, ovarian cancer, melanoma, prostrate cancer, colon cancer, glioma or astioblastomia in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 5. A method of lowering cholesterol, triglycerides, Lp(a), or LDL levels; inhibiting or treating hypercholesteremia; hyperlipidemia; cardiovascular disease; atherosclerosis; peripheral vascular disease; restenosis, or vasospasm; or inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula I, having the structure
- 6. A method of providing cognition enhancement or neuroprotection; or treating or inhibiting senile dementias, Alzheimer's disease, cognitive decline, stroke, anxiety, or neurodegenerative disorders in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 7. A method of treating or inhibiting free radical induced disease states in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 8. A method of inhibiting conception in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 9. A method of treating or inhibiting arthritis in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 10. The method according to claim 9, wherein the compound provided is 6-hydroxy-3,17β-dihydroequilenin, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate thereof, or a glucuronide thereof.
- 11. The method according to claim 9, wherein the compound provided is 6-hydroxyequilenin, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a sulfate thereof, or a glucuronide thereof.
- 12. The method according to claim 9, wherein the arthritis was rheumatoid arthritis, osteoarthritis, or spondyloarthropathies.
- 13. A method of treating or inhibiting joint swelling or erosion; or treating or inhibiting joint damage secondary to arthroscopic or surgical procedures in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 14. A method of treating or inhibiting infertility in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula 1, having the structure
- 15. A method of treating or inhibiting ischemia, reperfusion injury, asthma, pleurisy, multiple sclerosis, systemic lupus erythematosis, uveitis, sepsis, hemmorhagic shock, or type II diabetes in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula I, having the structure
Parent Case Info
[0001] This application claims priority from copending provisional application Serial No. 60/351,282, filed Jan. 23, 2002, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60351282 |
Jan 2002 |
US |